Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant dostarlimab plus CAPEOX vs CAPEOX in pMMR/MSS colon cancer
jRCT2051250048Phase 2Recruiting
- Sponsor
- GSK
- Start
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of dostarlimab in colon adenocarcinoma and colon cancer (2 arms), sponsored by GSK. Primary endpoints: Major pathological response (mPR) rate and Safety outcomes (AEs, SAEs, imAEs, AEs leading to death or discontinuation). Started Jul 2025; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
colon adenocarcinomacolon cancer
Beyond the preview
Go deeper on jRCT2051250048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250048.